trending Market Intelligence /marketintelligence/en/news-insights/trending/qS743-XWvFrW2Tt7LtMpPQ2 content esgSubNav
In This List

BioVie secures FDA's fast track designation for liver disease complication drug

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


BioVie secures FDA's fast track designation for liver disease complication drug

The U.S. Food and Drug Administration granted fast track designation to BioVie Inc.'s BIV201 for the treatment of refractory ascites, or the accumulation of protein-containing fluid in the abdomen, due to liver cirrhosis.

There are no drug therapies approved by the FDA to treat ascites specifically.

BioVie is evaluating the safety and indicator for potential efficacy of BIV201 in a phase 2a trial.